Emergent BioSolutions Inc., a Rockville-based biopharmaceutical firm, announced the submission of an Investigational New Drug application for the company?s Anthrax Immune Globulin with the U.S. Food and Drug Administration.
The product is a treatment for patients who present the symptoms of anthrax. Following the FDA?s 30-day review period, Emergent hopes to start the clinical trial period this year.
